EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cancer vaccine therapy based on peptides

Masahiro Katsuda, Hiroki Yamaue

Trends in Immunotherapy · 2017

DOI: 10.24294/ti.v1.i1.41 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Immunotherapy, 2017. Verfasst von Masahiro Katsuda und 1 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Following numerous unequivocal clinical failures, immunotherapy has become an attractive therapeutic modality. Peptide vaccines are cost-effective compared to other vaccine approaches, and effective epitopes eliciting strong immune response can be selected experimentally in silico and ex vivo. However, the clinical benefits of cancer peptides vaccine have been disappointing in most studies; therefore, we need to prove the clinical beneficial effects for cancer treatment following induction of more powerful cytotoxic T lymphocytes (CTLs). First, the choice of ideal target antigen is essential. Epitopes derived from tumor-associated antigens (TAAs), oncoantigens, vascular endothelial cells and neoantigens are then developed. In particular, whole-exome sequencing enables us to identify epitopes of neoantigens. The choice of therapeutic objectives is also important and peptide vaccines might be better to be developed as preventative vaccines. Dendritic cells (DCs) vaccine pulsed with peptides is an approach to induce powerful CTLs and might overcome several disadvantages of peptide vaccines as monotherapy. Targeting vaccine therapy against DC subsets in vivo is under development.Following numerous unequivocal clinical failures, immunotherapy has become an attractive therapeuticmodality. Peptide vaccines are cost-effective compared to other vaccine approaches, and effective epitopeseliciting strong immune response can be selected experimentally in silico and ex vivo. However, the clinicalbenefits of cancer peptides vaccine have been disappointing in most studies; therefore, we need to prove theclinical beneficial effects for cancer treatment following induction of more powerful cytotoxic T lymphocytes(CTLs). First, the choice of ideal target antigen is essential. Epitopes derived from tumor-associated antigens(TAAs), oncoantigens, vascular endothelial cells and neoantigens are then developed. In particular, wholeexomesequencing enables us to identify the epitopes of neoantigens. The choice of therapeutic objectives isalso important and peptide vaccines might be better to be developed as preventative vaccines. Dendritic cells(DCs) vaccine pulsed with peptides is an approach to induce powerful CTLs and might overcome severaldisadvantages of peptide vaccines as monotherapy. Targeting vaccine therapy against DC subsets in vivo isunder development.

Zitieren

APA

Katsuda, M., & Yamaue, H. (2017). Cancer vaccine therapy based on peptides. Trends in Immunotherapy. https://doi.org/10.24294/ti.v1.i1.41

Vancouver

Katsuda M, Yamaue H. Cancer vaccine therapy based on peptides. Trends in Immunotherapy. 2017. doi:10.24294/ti.v1.i1.41

BibTeX
@article{Katsuda2017,
  author = {Katsuda, Masahiro and Yamaue, Hiroki},
  title = {Cancer vaccine therapy based on peptides},
  journal = {Trends in Immunotherapy},
  year = {2017},
  doi = {10.24294/ti.v1.i1.41}
}
Kostenlos starten →